Experiment 635130

Worktypes

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismTrifolium subterraneum (FABACEAE)
CitationHODGSON,JM: PUDDEY,IB: CROFT,KD: MORI,TA: RIVERA,J: BEILIN,LJ:. (1999). ISOFLAVONOIDS DO NOT INHIBIT IN VIVO LIPID PEROXIDATION IN SUBJECTS WITH HIGH-NORMAL BLOOD PRESSURE.. 145(1)
Amount utilized
Compound isolated
DiseaseTHIS STUDY ASSESSED THE EFFECTS OF A 55MG DAILY ISOFLAVONOID SUPPLEMENT ON URINARY F2-ISOPROSTANE CONCENTRATIONS IN SUBJECTS WITH HIGH-NORMAL BLOOD PRESSURE(BP). A TOTAL OF 59 SUBJECTS COMPLETED AN 8-WEEK PARALLEL DISIGN. RANDOMIZED. DOUBLE BLIND. AND PLACEBO-CONTROLLED STUDY. F2-ISOPROSTANES, ISOFLAVONOIDS AND CREATININE WERE MEASURED IN 24-H URINE SAMPLES TAKEN AT BASELINE AND AT THE END OF THE INTERVENTION. THERE WERE SIGNIFICANT INCREASES IN URINARY EXCRETION OF GENISTEIN (5.22+0.75 MG DAY. P<0.0001) AND DAIDZEIN (2.53+0.43 MG DAY.P<0.0001) IN THE GROUP TAKING THE ISOFLAVONOID SUPPLEMENT. CREATININE EXCRETION WAS SIGNIFICANTLY CORRELATED WITH F2-ISOPROSTANES AT BASELINE (R=0.45.P<0.01). AFTER ADJUSTMENT FOR BASELINE VALUES, THERE WAS NO SIGNIFICANT DIFFERENCE BETWEEN GROUPS IN CREATININE ADJUSTED POST-INTERVENTION F2-ISOPROSTANE CONCENTRATIONS (P=0.74). IN ADDITION, CHANGES IN GENISTEIN AND DAIDZEIN EXCRETION WERE NOT SIGNIFICANTLY CORRELATED WITH CHANGES IN F-2ISOPROSTANES IN THE ISOFLAVONOID TREATMENT GROUP. THESE RESULTS ARE NOT CONSISTENT WITH THE SUGGESTION THAT THE TWO SOY DERIVED ISOFLAVONOIDS HAVE IN VIVO ANTIOXIDANT ACTIVITY AT A LEVEL OF INTAKE ACHIEVABLE BY DIETARY MEANS AND IN SUBJECTS WITH HIGH-NORMAL BP.
Dose amountVAR MG
Number2
Qualitative resultINACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
ExtractTYPE EXT NOT STATED
GenderGIVEN TO BOTH SEXES